Insight Pharma Newsletter July 2023

Dear Reader :

This month’s edition of Citeline’s newsletter, developed in alliance with the IPA, spotlights not just the business storms that pharma is tackling but also the devastating impact of climate change on operations.

French biotech Transgene’s new CEO outlines efforts to turnaround the company's fortunes, while we tell you about the damage to Pfizer’s North Carolina plant hit by a tornado and its impact on US drug supplies.

There’s also a piece on AI software that can improve the effectiveness of cardiac ablation in patients with persistent atrial fibrillation.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA

Perspective From Industry Leaders


Ex-Novartis Oncology Leader Riva Takes On Challenge Of Transgene Turnaround	How Will Pfizer Plant’s Tornado Damage Impact Congress’s Drug Shortages Debate?
After AstraZeneca walked away from a oncolytic virus vaccine partnership in May, French biotech Transgene was in sore need of a new direction. ...	The stakes on Capitol Hill rose another notch as tornado hit supplies of sterile injectable drugs at North Carolina plant....

Licensing & Collaboration Agreements


Sanofi Adds To Immunology Pipeline In Collaboration With Recludix	Unpartnered Assets: On The Shelf Or Hidden Treasure?
French pharma gets global rights at the start of Phase II for the US biotech’s preclinical program for inhibiting the STAT6 protein in respiratory ...	A look at biopharma’s most highly valued yet unpartnered assets features Karuna, Ventyx and regular bridesmaid Ascendis.....

Next Gen R&D


In Alnylam’s Search For A Mass-Market Treatment, A Twice Yearly Blood Pressure Injection Could Fit The Bill	Bayer Consumer Health’s Evendon-Challis On The ‘Huge Potential’ Of OTC Digital Therapeutics, AI
Alnylam is using its RNA interference technology to target hypertension, which could create a true mass-market cardiovascular blockbuster drug ...	HBW Insight speaks to Bayer Consumer Health's head of R&D and chief scientific officer David Evendon-Challis about the opportunity...

Clinical Trials


Cardio Conversations: 'Trials, Trials, Trials!' Volta Has Big Ambitions For AI In EP	US FDA ‘Advancing Real-World Evidence Program’ Has First Entrants
In this edition of Cardio Conversations, Medtech Insight editor Reed Miller talked to Théophile Mohr Durdez, the CEO and co-founder of Volta Medical...	Agency is painting the new advice program as an attractive, ‘all-hands-on-deck’ option for sponsors beginning an RWE program for a new indication...

Citeline Contact

Poornachandra Tejasvi .K, Senior Director - Emerging Markets, India

Mobile: +91 9945273146
Email: poornachandra.tejasvi@citeline.com

Client Services: clientservices@citeline.com

IPA Contact

Name: Hari Pranav K
Email: haripranav.k@ipa-india.org